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ABSTRACT
The Korean Society of Maternal Fetal Medicine proposed the first Korean guideline on 
prenatal aneuploidy screening and diagnostic testing, in April 2019. The clinical practice 
guideline (CPG) was developed for Korean women using an adaptation process based on 
good-quality practice guidelines, previously developed in other countries, on prenatal 
screening and invasive diagnostic testing for fetal chromosome abnormalities. We reviewed 
current guidelines and developed a Korean CPG on invasive diagnostic testing for fetal 
chromosome abnormalities according to the adaptation process. Recommendations for 
selected 11 key questions are: 1) Considering the increased risk of fetal loss in invasive 
prenatal diagnostic testing for fetal genetic disorders, it is not recommended for all pregnant 
women aged over 35 years. 2) Because early amniocentesis performed before 14 weeks of 
pregnancy increases the risk of fetal loss and malformation, chorionic villus sampling 
(CVS) is recommended for pregnant women who will undergo invasive prenatal diagnostic 
testing for fetal genetic disorders in the first trimester of pregnancy. However, CVS before 
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9 weeks of pregnancy also increases the risk of fetal loss and deformity. Thus, CVS is 
recommended after 9 weeks of pregnancy. 3) Amniocentesis is recommended to distinguish 
true fetal mosaicism from confined placental mosaicism. 4) Anti-immunoglobulin should be 
administered within 72 hours after the invasive diagnostic testing. 5) Since there is a high risk 
of vertical transmission, an invasive prenatal diagnostic testing is recommended according 
to the clinician's discretion with consideration of the condition of the pregnant woman. 6) 
The use of antibiotics is not recommended before or after an invasive diagnostic testing. 7) 
The chromosomal microarray test as an alternative to the conventional cytogenetic test is 
not recommended for all pregnant women who will undergo an invasive diagnostic testing. 
8) Amniocentesis before 14 weeks of gestation is not recommended because it increases the 
risk of fetal loss and malformation. 9) CVS before 9 weeks of gestation is not recommended 
because it increases the risk of fetal loss and malformation. 10) Although the risk of fetal 
loss associated with invasive prenatal diagnostic testing (amniocentesis and CVS) may 
vary based on the proficiency of the operator, the risk of fetal loss due to invasive prenatal 
diagnostic testing is higher in twin pregnancies than in singleton pregnancies. 11) When a 
monochorionic twin is identified in early pregnancy and the growth and structure of both 
fetuses are consistent, an invasive prenatal diagnostic testing can be performed on one fetus 
alone. However, an invasive prenatal diagnostic testing is recommended for each fetus in 
cases of pregnancy conceived via in vitro fertilization, or in cases in which the growth of 
both fetuses differs, or in those in which at least one fetus has a structural abnormality. The 
guidelines were established and approved by the Korean Academy of Medical Sciences. This 
guideline is revised and presented every 5 years.
Keywords: Invasive Prenatal Diagnostic Testing; Amniocentesis; Chorionic Villus Sampling; 
CVS; Chromosome; Microarray
INTRODUCTION
Prenatal diagnosis is an important aspect of obstetrics as it can identify structural or 
functional abnormalities in a developing and growing fetus. Information on prenatal 
diagnosis is used for fetal treatment and monitoring and determination of delivery 
method, which can be divided into two (prenatal screening testing and invasive diagnostic 
testing). Prenatal screening testing include maternal serum screening and ultrasound 
examinations. Recently, as a prenatal screening test, the fetal DNA screening test via DNA 
analysis of a pregnant women's blood sample has been developed and used worldwide. 
Moreover, it has been utilized in clinical trials conducted not only in other countries but 
also in Korea. Prenatal screening testing can be safely performed on pregnant women and 
fetuses. However, this test can be used only for estimating the risk of fetal chromosomal 
abnormalities, and cannot be used as a confirmatory test.1
Chorionic villus sampling (CVS), amniocentesis, and cordocentesis are invasive diagnostic 
testing used for diagnosing genetic or congenital diseases. Invasive diagnostic testing can 
directly examine the chromosomes of a fetus by invasively collecting fetal villi (placenta), 
amniotic fluid, and umbilical cord blood samples. Moreover, they can detect the presence of 
chromosomal abnormalities in a fetus, with an accuracy rate of nearly 100%.1,2
Since the specimen must be collected via the uterus, the testing must be performed by a 
highly skilled expert. Its disadvantage is that it is expensive. Moreover, serious complications, 
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such as miscarriage, bleeding, and infection, may occur. The fetal abortion rate within 2 
weeks after the procedure is about 3%.3,4 Therefore, invasive diagnostic testing cannot be 
performed on all pregnant women. Clinical examination guidelines on testing and methods 
used are necessary. Although there are several existing clinical treatment guidelines already 
known in other countries, they have not yet been properly developed. By establishing 
domestic medical guidelines on prenatal diagnosis tests, we can reduce unnecessary invasive 
tests in the future and can prevent false artificial abortion. Moreover, these guidelines can 
facilitate health promotion.
In relation to this reason, clinical practice guidelines (CPG) are required to determine 
which prenatal diagnosis method should be used. Although there are several CPGs already 
known in other countries, those in Korea have not yet been properly developed. Hence, the 
establishment of domestic CPGs on prenatal diagnosis tests can promote national health 
by reducing unnecessary invasive tests and parental anxiety due to incorrect information. In 
addition, this CPG can be used as a basis for establishing an effective prenatal management 
system at the government level and for overcoming low birth rate. Furthermore, it can be 
utilized as basic research data for the development of a new prenatal diagnosis method for 
effective prenatal care.
After reviewing the guidelines developed in other countries that have already been 
universalized previously, the establishment of a new clinical question is considered 
insignificant. Rather, the development of medical guidelines that combine recommendations 
and contents based on high-quality CPGs in other countries will be advantageous. Therefore, 
a CPG for invasive diagnostic testing was developed using the adaptation process.
METHODS
Process of guideline development
After reviewing the existing guidelines in other countries, the Korean CPG on invasive 
diagnostic testing (https://www.guideline.or.kr/evaluation/sub2.php) was developed using 
the adaptation process.
Establishment of a CPG committee
The working committee was organized by the Korean Society for Maternal Fetal Medicine 
(KSMFM). To define key questions for CPG, the committee comprised 12 maternal fetal 
medicine specialists and 11 methodology experts from medical schools and hospitals. 
Moreover, they conducted planning, guideline search, selection of key clinical questions, 
guideline assessment, selection, and adaptation to develop the guidelines.
Process of CPG development
1) Guideline search
PubMed, Embase (Elsevier version), and Cochrane Library were explored to collect all 
types of published CPG. Previous studies on invasive prenatal testing for fetal chromosome 
abnormalities were searched using the following key words: ‘practice guidelines,’ 
‘guidelines,’ ‘recommendation,’ ‘level of evidence,’ and ‘evidence grade.’ CPGs without 
recommendations, those that are outdated, those with unrelated topic, or those with missing 
data were excluded. After further elimination of duplicates, 41 guidelines were finally selected 
for review.
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2) Selection of key clinical questions
Initially, 12 key questions were tentatively selected based on the needs and public opinion of 
clinicians. The importance and urgency of the key questions were assessed using a 5-point 
Likert scale. Those rated as ≥ 4 by > 90% of the respondents were included as key questions 
according to the modified Delphi method, which was described in previous studies.5 Multiple 
repeat surveys have reduced the key question from 12 to 11. The final question was edited and 
revised to ensure consistency and clarity of grammar.
3) Guideline assessment, selection and adaptation
To evaluate the quality of the selected guidelines, we used the Korean Appraisal of Guidelines 
for Research & Evaluation II (K-AGREE II), which was approved by the AGREE Research 
Trust.6 Fifteen existing guidelines have been identified as potentially suitable for adaptation. 
Based on the results of the K-AGREE II evaluation, a recommendation matrix with 15 final 
guidelines was prepared. The recommendations for 11 major questions were compiled based 
on the guidelines selected by three authors.
4) Additional search of evidence
The references were reviewed based on the selected guidelines to assess the level of evidence.
5) Writing guidelines and determining the recommendation level
The guidelines were assessed and evidence was summarized. The level of evidence (Table 1)  
and recommendations (Table 2) were determined based on the Scottish Intercollgeate 
Guideline Network translated into Korean by the National Evidence-Based Healthcare 
Collaborating Agency (NECA, https://www.guideline.or.kr/evaluation/file/koreaguide.pdf ).7
6) Consensus methodology for guideline adoption
The members of the KSMFM subcommittee were instructed to provide a score for each draft 
recommendation using a 9-point Likert scale. A score of 1 indicates strong disagreement and 
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Table 1. Levels of evidence from the ‘SIGN Grading System 1999–2012’
Levels Definition
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low-risk of bias
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low-risk of bias
1− Meta-analyses, systematic reviews, or RCTs with a high-risk of bias
2++ High quality systematic reviews of case control or cohort or studies
High quality case control or cohort studies with a very low-risk of confounding or bias and a high probability that the relationship is causal
2+ Well-conducted case control or cohort studies with a low-risk of confounding or bias and a moderate probability that the relationship is 
causal
2− Case control or cohort studies with a high-risk of confounding or bias and a significant risk that the relationship is not causal
3 Non-analytic studies, e.g., case reports, case series
4 Expert opinion
SIGN = Scottish Intercollegiate Guidelines Network, RCT = randomized controlled trial.
Table 2. Grades of recommendations from the ‘SIGN Grading System 1999–2012’
Grades Definition
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence 
consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of 
results; or Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of 
results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+
SIGN = Scottish Intercollegiate Guidelines Network, RCT = randomized controlled trial.
9 strong consent. The average of each voting score was calculated, and it was used to assign 
items to one of three groups: 1–3 (disagreement), 4–6 (neutrality), and 7–9 (agreement). 
Based on these scores, the degree of consensus was evaluated.
7) Assessment and review conducted by external experts
There was a public hearing on the background, contents, and evidence of the guidelines 
during the 24th KSMFM Conference held in Seoul in June 2018.
8) Approval
After several revisions by the working committee, the guidelines were finally approved by the 
Korean Academy of Medical Sciences in March 2019.
Patients for whom the guidelines are applicable
The main target population is pregnant women in Korea. The major topic is invasive 
diagnostic testing for fetal chromosome abnormalities. The query for literature search was 
made with consideration of the target population and potential audience.
Professionals for whom the guideline is recommended
The primary users of this guideline are physicians who care for pregnant women. These 
guidelines can be used by medical students for learning purposes or as a reference for 
pregnant women to obtain the latest medical knowledge.
Principles and methods of guideline updates
The developed guidelines are listed on the website of the Korean Medical Guidelines Information 
Center (‘Clinical Practice Guidelines for Prenatal Aneuploidy Screening & Diagnostic Tests,’ 
https://www.guideline.or.kr/guide/view.php?number=1085&cate=A). Feasibility within the 
national insurance system will be reviewed and re-evaluated. The guidelines are revised every 5 
years after publication. The KSMFM Committee is responsible for this update.
RESULTS
Key questions and recommendations
•  KQ1. Should an invasive prenatal diagnostic testing for fetal genetic disorders be 
recommended for all pregnant women aged over 35 years?
Recommendation: Considering the increased risk of fetal loss in invasive prenatal diagnostic 
testinging for fetal genetic disorders, it is not recommended for all pregnant women aged 
over 35 years (Level of evidence: 2++, recommendation grade: B).
Summary of evidence: In older pregnant women, there is a high risk of complications, such 
as infertility, fetal malformations, gestational diabetes, and hypertension.8-10 In the past, 
pregnant women aged 35 years or older (32 years or older in the case of twin pregnancies) 
belonged to the high-risk group. Hence, invasive prenatal diagnostic testing for fetal genetic 
disorders is recommended.11,12 However, several studies have shown that age itself (over 35 
years) is not a risk factor for chromosomal abnormalities, such as submicroscopic partial 
imbalances.13 Considering the risk of fetal loss based on an invasive diagnostic test, invasive 
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prenatal diagnostic testing for fetal genetic disorders is not recommended for all pregnant 
women aged over 35 years.1,14
 
•  KQ2. Is CVS better than amniocentesis among pregnant women who will undergo 
invasive prenatal diagnostic testing for fetal genetic disorders in the first trimester of 
pregnancy?
Recommendation: Because early amniocentesis performed before 14 weeks of pregnancy 
increases the risk of fetal loss and malformation, CVS is recommended for pregnant women 
who will undergo invasive prenatal diagnostic testing for fetal genetic disorders in the first 
trimester of pregnancy. However, CVS before 9 weeks of pregnancy also increases the risk of 
fetal loss and deformity. Thus, CVS is recommended after 9 weeks of pregnancy (Level 1+, 
Grade A).
Summary of evidence: The World Health Organization (WHO) analyzed their CVS data. 
Results showed that when CVS is performed after 10 weeks of pregnancy, the procedure itself 
does not increase the fetal loss rate or cause fetal deformities, except in cases of fetal death 
or malformation due to abnormalities that the fetus initially had. The WHO stated that CVS 
is the only method used for the prenatal diagnosis of genetic and chromosomal diseases in 
early pregnancy, and it can be safely performed by a highly skilled individual.15 In addition, in 
the study of Kuliev et al.16, which performed CVS between 9 and 12 weeks of pregnancy, the 
risk of fetal limb reduction defects did not increase in the general population. The incidence 
of limb reduction defects after CVS was 5.2–5.7 per 10,000 people, and the incidence rate in 
the general population was 4.80–5.97 per 10,000 people.
By contrast, in a study conducted on 1,916 patients who had early amniocentesis (before 
13 weeks of gestation) and 1,775 individuals who had mid-trimester genetic amniocentesis 
(after 15 weeks of pregnancy), the rate of fetal loss in women who had early amniocentesis 
was significantly higher than that in women who had mid-trimester amniocentesis (7.6% 
vs. 5.9%, P = 0.012).17 The incidence of equinovarus in the early amniocentesis group was 
also significantly higher than that in the mid-trimester amniocentesis group (1% ± 3% vs. 
0% ± 1%, P < 0.001). The incidence of membrane rupture associated with the procedure was 
significantly higher in the early and mid-trimester amniocentesis groups (3.5% vs. 1.7%, P < 
0.001).17 In other studies, early amniocentesis conducted before 13 weeks of gestation was 
associated with a significantly higher fetal loss rate and incidence of equinovarus compared 
with mid-trimester amniocentesis group.18,19 Sundberg et al.20 conducted a study comparing 
early amniotic puncture (11–13 weeks of pregnancy) and CVS (10–12 weeks of pregnancy). 
Results showed that the incidence of fetal equinovarus in the early amniocentesis group 
significantly increased. Moreover, there was a significantly higher number of amniotic fluid 
leakage cases after the procedure. The fetal loss rates were 4.8% (n = 27) in the CVS group 
and 5.4% (n = 30) in the early amniocentesis group (P = 0.66).
Meanwhile, Brambati et al.21 showed that the fetal loss rate within the first 4 weeks after 
CVS performed at 6–7 weeks of gestation was significantly higher than after CVS performed 
at later gestational weeks (7.2% vs. 2.5%). Moreover, they reported that when CVS was 
performed in early pregnancy, the blood vessels of the chorionic plate could be damaged. 
This leads to hypoxic damage in the embryo since the boundary of the placenta cannot 
be clearly observed on ultrasonography and the path of the needle is difficult to control. 
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Therefore, CVS is advantageous compared with early amniocentesis conducted in the first 
trimester of pregnancy. However, CVS should be prevented in early pregnancy.
 
• KQ3. What should we do when the CVS results indicate mosaicism?
Recommendation: Amniocentesis is recommended to distinguish true fetal mosaicism from 
confined placental mosaicism (Level 2++, Grade C).
Summary of evidence: Mosaicism occur when maternal cells are contaminated with fetal 
specimens after an invasive prenatal diagnosis, which may achieve false-positive results. 
To prevent this phenomenon, amniocentesis must be conducted away from the placenta if 
possible. The first 1–2 mL of amniotic fluid should be discarded with the syringe, and the 
remaining sample should be collected with a new syringe. When the CVS results indicate 
mosaicism, amniocentesis is recommended to determine whether it is localized in the 
placenta. In a retrospective study of 11,200 patients who underwent CVS, the incidence rate 
of mosaicism was 1.3%, and it was confined to the cytotrophoblast of the placenta. However, 
approximately 90% of patients had normal amniocentesis results. 22 Mosaicism confined to 
the placenta causes pregnancy complications, such as fetal growth restriction and fetal death 
due to placental dysfunction. However, there is no chromosomal abnormality observed in the 
fetus itself.11 In a retrospective study of 115 patients who underwent CVS and 230 controls, 
the incidence rates of stillbirth, preterm birth, pre-eclampsia, and gestational diabetes 
were similar. However, patients who underwent CVS had a three-fold higher fetal growth 
restriction.23 Localized placental mosaicism can be associated with trisomy or uniparental 
disomy (UPD), which can cause fetal abnormalities if an imprinted gene is present on a 
particular chromosome. Chromosomes 6, 7, 11, 14, and 15 are monophilic chromosomes 
that can cause phenotypic abnormalities. Hence, if there is mosaicism with trisomy in these 
chromosomes, the UPD test using a single nucleotide polymorphism (SNP) array should 
be considered when performing amniocentesis. In particular, Prader-Willi syndrome and 
Angelman syndrome are UPD-related diseases. Therefore, when the CVS result indicates 
chromosomal mosaicism, genetic counseling and amniocentesis may be recommended.1,11,14 
Parents should be informed that assessments are important after childbirth because the fetus 
can have either a normal or abnormal development.
 
•  KQ4. In the case of pregnancy between Rh-negative women and Rh-positive men, should 
immunoglobulins be administered after an invasive prenatal diagnostic testing?
Recommendation: Anti-immunoglobulin should be administered within 72 hours after the 
invasive diagnostic testing (Level 2++, Grade B).
Summary of evidence: In a prospective study, of 655 Rh-negative pregnant women who 
underwent amniocentesis, 361 gave birth to Rh-positive newborns.24 Five (1.4%) patients 
who did not receive anti-D immunoglobulin vaccine developed antibodies. However, 
none of the newborns presented with abnormalities. Of 115 Rh-negative pregnant women 
underwent amniocentesis, those who gave birth to Rh-positive newborns were included 
in the analysis.25 Approximately 3.4% of women who underwent amniocentesis were 
sensitized. This rate was higher than that of women who did not undergo amniocentesis 
and were sensitized. In addition, sensitization was commonly performed before 28 weeks of 
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pregnancy. Of four sensitized newborns, two had exchange transfusions; however, during 
follow-up, the children did not present with specific developmental disorders at the age of 
2 years. The clinical guidelines of RCOG in 2011 showed that the volume of maternal fetal 
blood loss was significantly associated with the production of anti-D antibody.26 In the UK, 
Rh-negative pregnant women have been receiving anti-D immunoglobulins after delivery 
since 1969. This clinical guideline shows that before 1969, 46 per 100,000 newborns died 
from RhD alloimmune disease. However, the rate decreased to 1.6 per 100,000 newborns in 
1990. However, even if these clinical guidelines are followed, alloimmune diseases cannot 
be completely prevented. About 18%–27% of women who receive anti-D immunoglobulin 
after 28 weeks during their first pregnancy develop alloimmune diseases. Therefore, vaccines 
must be provided before this time. For successful immunological prevention, anti-D 
immunoglobulins should be administered within 72 hours. Even if anti-D immunoglobulin 
was not administered within 72 hours, it must be provided within 10 days to protect the fetus 
to some extent.26
 
•  KQ5. If a pregnant woman has hepatitis B, C or AIDS, does an invasive diagnostic testing 
increase the incidence of vertical transmission?
Recommendation: Since there is a high risk of vertical transmission, an invasive prenatal 
diagnostic testing is recommended according to the clinician's discretion with consideration 
of the condition of the pregnant woman (Level 2++, Grade B).
Summary of evidence:
1) Hepatitis B 
The vertical transmission rate was approximately 15% in women who tested positive for 
hepatitis B antigen but did not receive immunological prophylaxis. In pregnant women 
with hepatitis B e-antigen (HBeAg) and hepatitis B surface antigen (HBsAg), the vertical 
transmission rate was ≥ 90%. Therefore, immunological prophylaxis is important because 
it can reduce the vertical transmission rate to 1.5% in women who tested positive for hepa-
titis B antigen and up to 10% in those who tested positive for HBeAg.27 In a cohort study of 
pregnant women who tested positive for hepatitis B antigen, the risk of vertical transmis-
sion was about three times higher in those who experienced amniotic fluid puncture.28 
When the virus level was low, there was no significant difference in the vertical transmis-
sion rate. However, when the virus level was 7 log10 copies/mL or higher, the rate was as 
high as 50% in women who underwent amniocentesis. In other studies, the vertical trans-
mission rate was not high in pregnant women who tested negative for HBeAg compared 
with those who tested positive for HBeAg.29,30 In 2014, the Society of Obstetricians and 
Gynaecologists of Canada (SOGC) stated that amniocentesis, which is performed without 
the needle passing through the placenta, may reduce vertical transmission in pregnant 
women who tested positive for HBeAg. However, there is no sufficient clinical evidence 
that can support this notion.31 In the case of pregnant women with HBeAg, it is important 
for her to undergo HBV copy number test before invasive prenatal testing. When virus 
copy level is high, administration of an antiviral drug should be considered before the 
invasive prenatal testing, or the test should be re-determined.
2) Hepatitis C 
According to a report by the American College of Obstetricians and Gynecologists (ACOG) 
in 2007, there was no significant difference in terms of the vertical transmission rate 
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between pregnant women with hepatitis C who underwent amniocentesis and those who 
did not.32 Delamare et al.33 conducted a study on 22 pregnant women with hepatitis C. 
Of these patients, 16 who underwent amniocentesis in the second trimester of pregnancy 
were assessed. Hepatitis C virus RNA was found in the amniotic fluid in one patient. How-
ever, none of the newborns, including one whose amniotic fluid samples after birth tested 
positive, had the virus. Therefore, even if the data analyzed were limited, the current study 
presented a low vertical transmission rate.
3) AIDS 
wAmniocentesis is an extremely significant risk factor for vertical transmission even in 
patients who received antiviral drugs. A retrospective study assessed 553 pregnant women 
with AIDS, and results showed that the risk of vertical transmission was four times higher 
in those who underwent amniocentesis than in those who did not.34 However, with 
multiple highly active antiviral therapies, the rate of vertical transmission has decreased. 
Maiques et al.35 conducted a comparative study before and after 1997 when the use of anti-
viral treatment began. The vertical transmission rates were 30% among pregnant women 
who underwent amniocentesis before 1997 and 16.2% among those who did not. However, 
the rate decreased to 0% after 1997. Subsequently, Mandelbrot et al.36 compared highly ac-
tivated antiviral therapy with zidovudine monotherapy, with vertical transmission rates of 
0% and 6.1%, respectively. Hence, the highly activated antiviral therapy was found to have 
an excellent effect. By contrast, if no treatment was provided, the vertical transmission 
rate was 25%. Somigliana et al.37 and Shapiro et al.38 have reported that if pregnant wom-
en with AIDS have a low viral load or if they have received highly activated antiviral therapy 
before pregnancy or have started this therapy at least 2 weeks prior to amniocentesis even 
though they have a high viral load, the vertical transmission rate may not be high. Studies 
about the effect of CVS on vertical transmission among pregnant women with AIDS are 
limited. In the case of a pregnant woman with hepatitis B, C or AIDS, invasive diagnostic 
testing are recommended with caution because they may increase the incidence of vertical 
transmission.1,14,31,39,40
 
• KQ6. Should antibiotics be used before or after an invasive diagnostic testing?
Recommendation: The use of antibiotics is not recommended before or after an invasive 
diagnostic testing (Level 2++, Grade B).
Summary of evidence: Giorlandino et al.41 conducted a prospective randomized control 
trial at the largest center in Italy in 2009. Unlike previous studies, this study showed that the 
use of antibiotics reduced the incidence of miscarriage or premature rupture of membranes 
among women who underwent amniocentesis. This result is in accordance with that of 
previous studies.42-44 In 2007, a retrospective study revealed that there was no difference in 
terms of the incidence of complications between the group who received antibiotics and the 
group who did not.45 In 2012, a systematic review of studies did not confirm the efficacy of 
antibiotics.46 Therefore, the International Society of Ultrasound in Obstetrics & Gynecology 
(ISUOG) and the SOGC do not recommend the use of antibiotics when performing an 
invasive prenatal diagnostic testing.47 No randomized controlled trial has assessed the 
efficacy of prophylactic antibiotics in women who underwent cordocentesis. Boulot et al.48 
reported that antibiotics can be used to reduce the risk of fetal death when performing 
cordocentesis. However, other studies have reported that the complications were not caused 
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by sterile manipulation alone without antibiotics.49-52 The ACOG does not recommend the 
use of antibiotics to prevent intrauterine infections before an invasive diagnostic testing.32
 
•  KQ7. Can the chromosomal microarray test be used as an alternative to the conventional 
cytogenetic test for pregnant women who will undergo an invasive prenatal diagnostic 
testing?
Recommendation: The chromosomal microarray (CMA) test as an alternative to the 
conventional cytogenetic test is not recommended for all pregnant women who will undergo 
an invasive diagnostic testing (Level 2++, Grade B).
Summary of evidence: In 2012, Wapner et al.53 conducted a multicenter study comparing 
the conventional cytogenetic test and CMA with the help of the National Institute of Child 
Health and Human Development in the United States. The CMA included all conventional 
cytogenetic test results, and it was more advantageous than cytogenetic testing among fetuses 
who presented with one or more major malformations on ultrasonography. In particular, 
based on the CMA results, 6.0% of fetuses with normal cytogenetic test results but with 
structural abnormalities on prenatal sonography presented with clinically significant deletions 
or duplications. In cases where the NT thickness was > 3.5 mm, the CMA results indicated a 
high incidence rate of pathogenic copy number variation (CNV) even though the cytogenetic 
test results were normal.54,55 By contrast, in pregnant women who underwent cytogenetic 
testing due to maternal old age or an abnormal maternal serum screening test result, if there 
were no structural fetal abnormalities on ultrasonography and no abnormal cytogenetic test 
results, only 1.7% presented with significantly abnormal CMA results. In a systematic review 
of previous studies, CMA abnormalities were found in approximately 6.5% of fetuses with 
normal cytogenetic test results but with structural abnormalities, and CMA abnormalities were 
confirmed in 1.0%–1.1% of fetuses with normal cytogenetic and ultrasonographic results.56 
CMA is superior to cytogenetic testing in terms of technology. In particular, the time from 
sample collection to reporting can be decreased because the cells do not need to be cultured. 
In addition, the test report rate of CMA was higher in stillborn fetuses, and a higher number 
of genetic test results could be confirmed compared with that of cytogenetic test results.57 
However, there are several limitations. That is, it is difficult to clinically and accurately explain 
whether a specific CMA result has never been reported before or if gene duplication mutations 
with various clinical results will appear. CMA often report test results as benign, pathologic, 
and uncertainty of variation (VUS). Approximately 1.4% of cases involved VUS. CMA tests 
cannot be used to diagnose chromosomal balance translocations or inversions, and less than 
20% of mosaicism is difficult to detect using CMA. Based on several guidelines, microarray 
tests should be performed when a fetus present with structural abnormalities or when invasive 
diagnostic genetic tests are performed on a stillborn child.14,58,59
 
• KQ8. Can amniocentesis be performed before 14 weeks of gestation?
Recommendation: Amniocentesis before 14 weeks of gestation is not recommended because 
it increases the risk of fetal loss and malformation (Level 1++, Grade A).
Summary of evidence: A previous study has compared 1,916 patients who had early 
amniocentesis (before 14 weeks of pregnancy) and 1,775 patients who underwent mid-
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trimester amniocentesis (after 15 weeks of pregnancy). Results showed that the rate of fetal 
loss was significantly higher in those who had early amniocentesis than in those who had 
mid-trimester amniocentesis (7.6% vs. 5.9%, P = 0.012).17 The incidence rate of equinovarus 
was significantly higher in the early amniocentesis group than in the mid-trimester 
amniocentesis group (1% ± 3% vs. 0% ± 1%, P < 0.001). Membrane rupture due to the 
procedure was significantly higher in the early amniocentesis group than in the mid-trimester 
amniocentesis group (3.5% vs. 1.7%, P < 0.001).17 In a previous study, the risk of club 
foot in patients who had early amniocentesis was 10 times higher than that of the normal 
population. The incidence rate of bilateral club foot was high in the early amniocentesis 
group.19 In a study by Sundberg et al.,20 the incidence rate of equinovarus was significantly 
higher, and amniotic fluid leakage was more commonly observed in the early amniocentesis 
group than in the mid-trimester amniocentesis group. Winsor et al.18 has shown that early 
amniocentesis was associated with an increased rate of fetal loss.
 
• KQ9. Can CVS be performed before 9 weeks of gestation?
Recommendation: CVS before 9 weeks of gestation is not recommended because it increases 
the risk of fetal loss and malformation (Level 2++, Grade B).
Summary of evidence: CVS is the only method used for the prenatal diagnosis of genetic and 
chromosomal diseases in early pregnancy, and it can be safely performed by an expert.15 The 
WHO analyzed their CVS data. Results showed that if CVS was performed after 10 weeks of 
pregnancy, the procedure itself did not increase the fetal loss rate and did not cause birth 
defects, except in the case of fetal death due to fatal malformations inherent to the fetus.15,60 
In a previous study, when CVS was performed between 9 and 12 weeks of gestation, the 
risk of fetal limb reduction defects was not higher than that of the general population. The 
incidence rate of limb loss defects after CVS was 5.2–5.7 per 10,000 people, and the incidence 
rate in the general population was 4.8–6.0 per 10,000 people.16 However, CVS performed 
before 10 weeks of gestation is associated with a higher risk of fetal loss, fetal limb defects, 
and facial malformations compared with CVS conducted after 10 weeks of pregnancy. 
Botto et al.61 reported that the transverse digital deficiencies (TDDs) of the fetus were more 
commonly observed when CVS was performed before 11 weeks of pregnancy. Moreover, 
they showed that early CVS is correlated with an increased risk of fetal TDD. Moreover, other 
studies showed a higher incidence of fetal limb loss when early CVS was performed.62,63 
Brambati et al.21 showed that the incidence rates of fetal loss were significantly higher 
within the first 4 weeks after the test in women who underwent early CVS (at 6–7 weeks of 
gestation) than in those who underwent late CVS (7.2% vs. 2.5%). When CVS is performed in 
early pregnancy, the borders of the placenta cannot be observed clearly on ultrasonography, 
and it is difficult to control the path of the needle, which can damage the blood vessels of 
the chorionic plate and can subsequently lead to hypoxic injury in the embryo. Kuliev et 
al.16 showed that unnecessary procedures can be prevented among embryos with prenatal 
death-related diseases that can be diagnosed on ultrasonography after 9 weeks of pregnancy. 
Hence, CVS should be performed after 9 weeks of gestation.
 
•  KQ10. Is the risk of fetal loss due to an invasive prenatal diagnostic testing higher in twin 
pregnancy than in singleton pregnancy?
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Recommendation: Although the risk of fetal loss associated with invasive prenatal diagnostic 
testing (amniocentesis and CVS) may vary based on the proficiency of the operator, the risk 
of fetal loss due to invasive prenatal diagnostic testing is higher in twin pregnancies than in 
singleton pregnancies (Level 2++, Grade C).
Summary of evidence: Recent studies have revealed the risk of fetal loss after amniocentesis. 
In 2006, the case-control study of Millaire et al.64 reported that the risk of fetal loss after 
amniocentesis was 3.0%. Meanwhile, in 2013, Lenis-Cordoba et al.65 showed that the risks 
of fetal loss in women who underwent amniocentesis and those who did not were 2.7% and 
0.8%, respectively. In another study, the risk of fetal loss after amniocentesis conducted 
during the mid-trimester in a twin pregnancy was 3.2%.66 A meta-analysis showed that 
the overall risk of fetal loss due to amniocentesis was 3.07%, and the risk of fetal loss at 24 
weeks before pregnancy was 2.54%. Moreover, the fetal loss rate was 2.59% in case-control 
studies.67 Studies on the risk of fetal loss after CVS are still limited. However, a meta-
analysis showed that the risk of fetal loss after CVS was 3.84%.67 CVS can be performed 
using several methods, which were as follows: testing via the abdomen or the cervix, use of 
one or two needles, and testing once or twice via the uterus. The risk of fetal loss between 
these methods did not significantly differ.67 In a study comparing the risk of fetal loss due to 
amniocentesis and the risk of fetal loss due to CVS, the fetal loss rates were 2.9% and 3.2%,68 
4.0%, and 3.85% (P= 0.95, log rank test),69 respectively. There were no significant differences 
between the two methods. When planning CVS or amniocentesis, the risk of fetal loss should 
be considered. Only few studies have compared the risk of fetal loss between singleton and 
twin pregnancies. However, the risk of fetal loss was higher in twin pregnancies than in 
singleton pregnancies.66,67,69
 
•  KQ11. When performing an invasive prenatal diagnostic testing in a monochorionic twin 
pregnancy, is it sufficient to test one fetus alone?
Recommendation: When a monochorionic twin is identified in early pregnancy and the 
growth and structure of both fetuses are consistent, an invasive prenatal diagnostic testing 
can be performed on one fetus alone. However, an invasive prenatal diagnostic testing is 
recommended for each fetus in cases of pregnancy conceived via in vitro fertilization (IVF), or 
in cases in which the growth of both fetuses differs, or in those in which at least one fetus has 
a structural abnormality (Level 2++, Grade B).
Summary of evidence: When performing amniocentesis in dichorionic twin pregnancies, 
both fetuses should be tested using different needles. In the case of amniocentesis using 
this method, the risk of duplicating tests on one fetus is about 1.8%.70-72 Moreover, indigo 
carmine should be injected into the amniotic cavity prior to the removal of the needle 
during amniocentesis of the first fetus to prevent duplicate testing. Methylene blue is not 
recommended due to the risk of fetal malformation.73,74 When amniocentesis is performed 
in a monochorionic twin pregnancy, the examination of one fetus alone may be sufficient. 
This method can be used when a monochorionic pregnancy is confirmed on ultrasonography 
before 14 weeks of pregnancy, and the growth and structure of the two fetuses must be 
similar. Otherwise, amniocentesis is recommended for both fetuses. In addition, in cases 
of IVF pregnancy, individual amniocentesis is recommended for the two fetuses,69,70,75,76 
because, intertwin crown-rump length discordance above 10% in the 1st trimester period 
is generally known to be associated with adverse perinatal outcome and chromosomal 
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anomaly.77 When there is more than 10% intertwin discordance of CRL, the risk of fetal 
chromosomal anomalies is 9.2%, the risk of structural anomalies is 14.0 to 27.3%, and the 
risk of spontaneous fetal loss less than 24 weeks is 15.0% to 25.0%.77-79 When there is more 
than 15% intertwin discordance, the risk of fetal chromosomal anomalies is 17.0%, the risk 
of structural anomalies is about 29.0%, and the risk of spontaneous fetal loss less than 24 
weeks is 17.0% to 37.1%.77,78 In dichorionic twin pregnancy, the placenta of both fetuses 
should be assessed using different needles. Sample errors due to cross-contamination have 
been reported in approximately 1% of cases.76,77,80,81 To prevent this risk, samples must be 
collected close to the area where the umbilical cord is attached if possible. This prevents 
collecting samples around the membrane, which separates the fetuses. When performing 
CVS in a monochorionic twin pregnancy, the test can be performed only once. In cases 
in which the growth or structure of the fetuses differs or in cases of IVF pregnancies, 
CVS should be avoided, and amniocentesis must be performed twice for each fetus.70,82 
However, whether an invasive prenatal diagnostic testing should be performed once in 
a monochorionic twin pregnancy or it must be conducted independently for each fetus 
remains controversial. Since there are cases in which fetuses have different chromosomes 
in monochorionic twin pregnancy,83,84 the number of tests should be determined based on 
several factors such as intertwin growth, structural anomaly, and types of fertilization.
SUMMARY
Invasive prenatal diagnostic testing has been recommended for women with advanced 
maternal age, particularly those with a previous history of pregnancy with a baby with 
chromosomal abnormalities, parents with a chromosomal abnormality, those with a 
significant medical history, those with a family history of hereditary diseases, or those at high 
risk of maternal serum screening. However, fetal loss or injuries may occur after the tests. 
Moreover, pregnant women should cover the high costs because invasive diagnostic testing 
in Korea are not covered by the national insurance. This guideline was developed to reduce 
unnecessary invasive prenatal diagnostic testing for fetal chromosome abnormalities by 
validating the target of the tests. Moreover, it aimed to present appropriate methods that can 
be used when performing diagnostic tests. Based on these guidelines, more effective prenatal 
management systems can be developed.
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